DANIEL J BOOSER to Time Factors
This is a "connection" page, showing publications DANIEL J BOOSER has written about Time Factors.
Connection Strength
0.047
-
Genomic index of sensitivity to endocrine therapy for breast cancer. J Clin Oncol. 2010 Sep 20; 28(27):4111-9.
Score: 0.008
-
Residual risk of breast cancer recurrence 5 years after adjuvant therapy. J Natl Cancer Inst. 2008 Aug 20; 100(16):1179-83.
Score: 0.007
-
Phase II trial of 10-EDAM in the treatment of metastatic breast cancer. Cancer Chemother Pharmacol. 2007 Jun; 60(1):61-7.
Score: 0.006
-
Gene expression profiles obtained from fine-needle aspirations of breast cancer reliably identify routine prognostic markers and reveal large-scale molecular differences between estrogen-negative and estrogen-positive tumors. Clin Cancer Res. 2003 Jul; 9(7):2406-15.
Score: 0.005
-
A Phase I study of docetaxel plus cyclophosphamide in solid tumors followed by a Phase II study as first-line therapy in metastatic breast cancer. Clin Cancer Res. 2003 Jul; 9(7):2426-34.
Score: 0.005
-
A detailed evaluation of cardiac toxicity: a phase II study of doxorubicin and one- or three-hour-infusion paclitaxel in patients with metastatic breast cancer. Clin Cancer Res. 2002 Nov; 8(11):3360-8.
Score: 0.005
-
Toxicity, immunogenicity, and induction of E75-specific tumor-lytic CTLs by HER-2 peptide E75 (369-377) combined with granulocyte macrophage colony-stimulating factor in HLA-A2+ patients with metastatic breast and ovarian cancer. Clin Cancer Res. 2002 Nov; 8(11):3407-18.
Score: 0.005
-
Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer. J Clin Oncol. 2002 Apr 01; 20(7):1800-8.
Score: 0.005